About Surf Bio
Surf Bio is a Healthcare company based in Palo Alto (United States) founded in 2021 by Bryan Mazlish, and was acquired by Halozyme in January 2026. Therapeutics for diabetes and other diseases are developed via biotechnology. Surf Bio has raised $16.02 million across 2 funding rounds from investors including Halozyme, Gates Foundation and Xontogeny. Its chief executive, as recorded, is Bryan Mazlish. Surf Bio offers products and services including Surf SnapShotâ„¢. Its focus areas include Life Sciences, Diabetes, Drugs and Oncology. Its competitors include Vir Biotechnology, Vaxcyte and Sana Biotechnology; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2021 and based in Palo Alto, United States, therapeutics are developed by Surf Bio for diabetes, oncology, infectious diseases, gene therapy, and related areas. A biotechnology platform is utilized to create solutions, with the primary focus on ultra-rapid insulin for diabetes management. Operations center on advancing these programs through research and development in the biotech sector.
Products & Services of Surf Bio
Surf Bio offers a comprehensive portfolio of products and services, including Surf SnapShot™.
Enables high-concentration subcutaneous injections for biologics and antibodies.
Funding Insights of Surf Bio
Surf Bio has successfully raised a total of $16.02M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $1.6 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $16.02M
- Total Rounds 2
- Last Round Grant — $1.6M
- First Round $16.02M
(Apr 2022)
- Investors Count 3
All 2 funding rounds of Surf Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2024 | $1.6M | Grant | – | – | |
| Apr 2022 | $16.02M | Seed | – | Breakout Ventures, Xontogeny | – |
4 investors in total: 4 institutional.
Investors in Surf Bio
Surf Bio has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Halozyme, Gates Foundation and Xontogeny.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investments in science-driven companies are made. | breakout.vc | |||
Life science startups are accelerated through focused programs by Xontogeny. | 2016 | xontogeny.com | Boston, United States | |
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
Drug delivery technologies for disease treatment are developed. | 1999 | halozyme.com | San Diego, United States |
Investor details for Surf Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Surf Bio
2 people are tracked at Surf Bio (2 in leadership).
| Name | Role | Group |
|---|---|---|
Bryan Mazlish | Founder & CEO | Leadership |
Eric Appel | Co-Founder and Chief Technical Advisor | Leadership |
Complete people profiles for Surf Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Surf Bio
4 dated milestones of Surf Bio across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Surf Bio is founded.
- Funding First funding round of $16.0M.
- Funding Latest funding round, Grant, of $1.6M.
- Exit Acquired by Halozyme.
Competitors of Surf Bio
Surf Bio has 3 listed competitors in our database, 3 of them funded. They include Vir Biotechnology, Vaxcyte and Sana Biotechnology.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases | |
| vaxcyte.com | 2013 | Foster, United States | $347M | 254 | Vaccines for infectious diseases are developed using cell-free protein synthesis. | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. |
Detailed competitors of Surf Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Surf Bio
The website of Surf Bio (surf.bio) receives about 2.2K visits a month.
- Monthly visits2.2K
▼ 49.5% vs previous month
Top companies in Diabetes
3 companies that operate in the same segment as Surf Bio (Diabetes) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Surf Bio
Complete news archive for Surf Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Surf Bio
Surf Bio was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Surf Bio is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Bryan Mazlish is the CEO of Surf Bio, as recorded in our data. They have also founded this company.
Surf Bio is a funded company, having raised a total of $16.02M across 2 funding rounds to date. The company's 1st funding round was a Seed of $16.02M, raised on Apr 2022.
Founded in 2021 and based in Palo Alto, United States, therapeutics are developed by Surf Bio for diabetes, oncology, infectious diseases, gene therapy, and related areas. A biotechnology platform is utilized to create solutions, with the primary focus on ultra-rapid insulin for diabetes management. Operations center on advancing these programs through research and development in the biotech sector.
Surf Bio's top competitors include Vaxcyte, Sana Biotechnology and Vir Biotechnology.
Surf Bio offers Surf SnapShotâ„¢.
Surf Bio has 4 investors. Key investors include Halozyme, Gates Foundation, Xontogeny, and Breakout Ventures.
Yes. Surf Bio was acquired by Halozyme in January 2026.